P114
Conclusion The data obtained show that further studies are required to improve personalized therapy for NSCLC patients. The frequency and type of KRAS and EGFR mutations were first assessed in NSCLC patients from West Siberia. This work was supported by a Grant from the OPTEK Company (No 122/2014/51/Nvs ).
Source: European Journal of Cancer Supplements - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Genetics | Grants | Lung Cancer | Molecular Biology | Non-Small Cell Lung Cancer | Study | Tarceva